Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT01277653 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of PIVKA-II and AFP Measurement in Surveillance Program for Early Detection of Hepatocellular Carcinoma

Start date: June 2007
Phase: N/A
Study type: Observational

There is no prospective study on the test intervals of alpha-fetoprotein (AFP) or on the role of prothrombin induced vitamin K absence or antagonist-II (PIVKA-II) in surveillance program for early detection of hepatocellular carcinoma(HCC). The goal of this study is to compare if the testing of AFP + PIVKA-II in intervals of 3 months is more effective in diagnosing early stages of HCC than the 6 month interval of AFP that is commonly used

NCT ID: NCT01266707 Recruiting - Clinical trials for Hepatocellular Carcinoma

Antiangiogenic Peptide Vaccine Therapy in Treating Patient With Hepatocellular Carcinoma

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess toxicities of angiogenic peptide vaccine therapy in treating HLA-A*2402 restricted patients with advanced hepatocellular carcinoma.

NCT ID: NCT01259193 Recruiting - Clinical trials for Hepatocellular Carcinoma

Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC

Start date: October 2010
Phase: Phase 2
Study type: Interventional

Sorafenib ,an oral multikinase inhibitor targeting several tyrosine-kinase receptors with antiangiogenesis and antiproliferation of HCC, is the first approved target therapy for HCC. Zoledronic acid is used for treatment of bone metastasis of diverse malignant cancer. Emerging data suggest that zoledronic acid may also exhibit anticancer properties. The objectives of the study is to evaluate the safety of Sorafenib combined with Zoledronic Acid and to evaluate overall survival and time to progression.

NCT ID: NCT01247506 Recruiting - Clinical trials for Hepatocellular Carcinoma

Different Genetic Features Associated With Hepatic Carcinogenesis

Start date: February 2010
Phase: N/A
Study type: Observational

The purpose of this study is to identify different genetic features in hepatocellular carcinoma. It will assist in predicting individual risks of disease progression and would help to clarify pathophysiological mechanisms of HCC.

NCT ID: NCT01170104 Recruiting - Clinical trials for Hepatocellular Carcinoma

Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC)

Start date: June 2009
Phase: Phase 2
Study type: Interventional

To evaluate the time to progression of the combination therapy of Transcatheter Arterial Chemoembolization (TACE) and sorafenib in patients with previously untreated advanced or metastatic hepatocellular carcinoma.

NCT ID: NCT01125020 Recruiting - Clinical trials for Hepatocellular Carcinoma

Impact of Postoperative Adjuvant Chemotherapy in Patients With Hepatocellular Carcinoma After Liver Transplantation

Start date: December 2008
Phase: N/A
Study type: Interventional

The study is designed to investigate the effect of postoperative adjuvant chemotherapy in prevention of tumor recurrence and metastasis for hepatocellular carcinoma after liver transplantation.

NCT ID: NCT01102335 Recruiting - Clinical trials for Hepatocellular Carcinoma

Synergistic Treatment for Hepatocellular Carcinoma (HCC) Using Transcatheter Arterial Chemoembolization (TACE) With Anti-hepatitis B Virus (Anti-HBV) Therapy

TACEHBV
Start date: April 2010
Phase: Phase 4
Study type: Interventional

The purpose of this study is to elucidate the influence of anti-hepatitis B virus therapy on safety and survival of HCC patient after transcatheter arterial chemoembolization.

NCT ID: NCT01033578 Recruiting - Clinical trials for Hepatocellular Carcinoma

Efficacy of Postoperative Adjuvant Treatments for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

Start date: October 1999
Phase: N/A
Study type: Interventional

The aim of this study is to assess efficacy of the different adjuvant chemotherapy strategies after hepatectomy and thrombectomy for hepatocellular carcinoma (HCC) and portal vein tumor thrombosis( PVTT).

NCT ID: NCT01024530 Recruiting - Clinical trials for Hepatocellular Carcinoma

Phase II/III Trial of Hepatocellular Carcinoma Patients Treated by ex Vivo Expanded Autologous Immune Killer Cells as the Adjunct Therapy

Start date: May 2009
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy of ex vivo expanded autologous immune killer cells in treating hepatocellular carcinoma patients in: 1. Reduction of tumor size 2. Reducing the relapse rate: Reducing the frequency of TACE treatment by IKC injections.

NCT ID: NCT00999843 Recruiting - Clinical trials for Hepatocellular Carcinoma

Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer

Start date: October 2009
Phase: Phase 1/Phase 2
Study type: Interventional

Patients with liver cancer will receive interventional therapy plus radiotherapy. Maintenance Sorafenib will be taken after the completion of radiotherapy. Hypothesis of the current study is that Sorafenib as a maintenance therapy is safe and superior to radiotherapy combined with interventional therapy in terms of survival in comparison to historical data.